statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dr Reddy's Labs shares in red after USFDA issues form 483 with four observations

The USFDA inspected Dr Reddy's manufacturing facility in Srikakulam in Andhra Pradesh between May 30 to June 7, 2024.

Dr Reddy's: US FDA issues form 483 with 4 observations for its Andhra facility

Post the observations, Dr Reddy's said that it will address the issues within the stipulated timeline.

Stock Radar: M&amp;M Financial, Biocon, Dr Reddys Labs, Sansera Engineering, Kalyan Jewellers in focus on Tuesday

Century Textiles, Suraj Estate Developers, Wipro, IFGL Refractories, Capacite Infraprojects, MOIL, Adani Power, Bharat Forge, 3i Infotech, and Jaiprakash Associates will also be in focus on Tuesday.

Neutral Dr Reddy’s Labs; target of Rs 6,070: Motilal Oswal

Motilal Oswal recommended accumulate rating on Dr Reddy’s Labs with a target price of Rs 6,070 in its research report dated May 07, 2024.

Dr Reddy’s to launch over 20 products in US in FY25

Dr Reddy’s reported better-than-expected net profit of Rs 1,307 crore for the March quarter, up 36 percent from the year-ago period

Dr Reddy's healthy Q4 results fail to impress brokerages amid lack of growth triggers

While Revlimid push helped Dr Reddy's report healthy Q4 earnings, a lack of strong US launch pipeline, high R&amp;D costs and weakness in base business are expected to put near-term pressure on the drugmaker.

Dr Reddy's Labs CFO Parag Agarwal to retire on July 31, MV Narasimham elevated

Agarwal will also cease to be a member of the Management Council and Senior Management Personnel of the company and will continue to be available with till August 31, 2024.

Dr Reddy's Q4 results: Net profit up 36% to Rs 1,307 crore, Rs 40/share dividend declared

Dr Reddy's Q4 earnings: Revenue rose 12 percent from a year earlier to Rs 7,083 crore

Three stocks that can deliver up to 10% in the short term; watch out for the rising VIX

The volatility index (VIX) bouncing back suggests challenges ahead, while on the downside, a breach below 22,300 could lead to a slide towards 22,100–22,000 on the Nifty.

Daily Voice | These 4 pharma stocks to benefit from change in 2 trends: HDFC Securities' Unmesh Sharma

The Head of Institutional Equities at HDFC Securities expects consumption demand to witness a slight pickup in FY25 and suggests adding exposure to the FMCG sector on a selective basis.

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Volume	410,391.00
52-Wk High	6,938.90
52-Wk Low	5,205.55

DRREDDY.NSE Dr. Reddy`s Laboratories Ltd.

About

Feed

News

Sentiment

Fundamentals